<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Affiliated Computer Services,</title>
	<atom:link href="http://www.stockbloghub.com/tag/affiliated-computer-services/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Brilinta Drug Stomps Plavix</title>
		<link>http://www.stockbloghub.com/2009/09/01/azn-astrazenecas-brilinta-drug-stomps-plavix/14006</link>
		<comments>http://www.stockbloghub.com/2009/09/01/azn-astrazenecas-brilinta-drug-stomps-plavix/14006#comments</comments>
		<pubDate>Tue, 01 Sep 2009 17:32:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services,]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14006</guid>
		<description><![CDATA[AstraZeneca (AZN) recently said that results from a phase III head-to-head trial showed that its Brilinta (ticagrelor) achieved greater efficacy in the primary endpoint, reduction of cardiovascular events, compared to Sanofi-Aventis (SNY)/Bristol-Myers’ (BMY) Plavix (clopidogrel). Brilinta significantly reduced the mortality rate from cardiovascular events, myocardial infarctions and strokes without increasing major bleeding, which is a side-effect of Plavix. However, the frequently reported side-effects of Brilinta included slower heart rhythms and dyspnoea. Brilinta is an investigational oral anti-platelet treatment being developed for acute coronary syndrome (ACS). Results from the 18,624 patient PLATO (A Study of Platelet Inhibition and Patient Outcomes) trial were presented at the European Society of Cardiology congress and published in the New England Journal of Medicine (NEJM). The data on Brilinta look compelling and could help the product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/01/azn-astrazenecas-brilinta-drug-stomps-plavix/14006/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NOVL) Novell Reports Mixed Results</title>
		<link>http://www.stockbloghub.com/2009/08/28/novl-novell-reports-mixed-results/13776</link>
		<comments>http://www.stockbloghub.com/2009/08/28/novl-novell-reports-mixed-results/13776#comments</comments>
		<pubDate>Fri, 28 Aug 2009 23:45:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Security Software & Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services,]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Novell Inc.]]></category>
		<category><![CDATA[NOVL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13776</guid>
		<description><![CDATA[Novell, Inc. (NOVL), a leading technology software company reported mixed third quarter results with revenue slightly below expectations and adjusted EPS marginally over. Revenue of $216.1 million in the quarter decreased 11.9% from the year-ago period and was 0.9% below the Zacks Consensus estimate. Adjusted EPS of 7 cents reported in the quarter did manage to edge out the Zacks Consensus Estimate by 1 cent. EPS increased 40.0% from the 5 cents reported in the year-ago period due to cost-cutting efforts. As a result of lower operating expenses, which fell 20.0% year over year, non-GAAP operating margin improved to 15.3% in the quarter from 9.9% in the year-ago quarter. Revenue declined due to a sharp drop in software license revenue, which fell 49.0% year over year as sales of identity ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/novl-novell-reports-mixed-results/13776/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

